Better tests to confirm or rule out aggressive prostate cancer
Analytic diagnosis methods for disease ruling
This project is creating new statistical and computer-based rules to help doctors more accurately tell who has aggressive prostate cancer and who does not.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11179434 on NIH RePORTER |
What this research studies
If you're facing prostate testing, this project is creating new ways to decide who really needs a biopsy or treatment. Researchers will combine PSA, other biomarkers, tissue and fluid samples, and clinical information to build rules that use several predictors at once. They will create a new performance metric tied to real clinical decisions and use statistical and computational methods to estimate how well the rules work. The hope is to avoid unnecessary biopsies and reduce overtreatment while making sure aggressive cancers are caught early.
Who could benefit from this research
Good fit: Men undergoing prostate cancer screening or diagnostic workup—especially those with elevated PSA, abnormal imaging, or uncertain biopsy results—would be most relevant.
Not a fit: People without prostate concerns, or men with clearly advanced or previously treated metastatic prostate cancer, would be unlikely to benefit directly.
Why it matters
Potential benefit: If successful, these methods could lower unnecessary prostate biopsies and better match treatment to men with aggressive disease.
How similar studies have performed: Existing tools like PSA tests, risk calculators, and prostate MRI help somewhat but can over-detect low-risk disease; tying formal analytic metrics to clinical decisions is relatively new and not yet widely proven.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Huang, Yijian — Emory University
- Study coordinator: Huang, Yijian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.